Doxazosin and Ramipril in Hypertension
- Registration Number
- NCT02901977
- Lead Sponsor
- Karolinska Institutet
- Brief Summary
Randomized double-blind parallel group study in patients with mild-to-moderate hypertension to evaluate the effects beyond the blood pressure lowering effect of treatment for 12 weeks with ramipril or doxazosin on hemostatic mechanisms and on endothelial function.
- Detailed Description
This study aims to answer the following questions: 1) Does antihypertensive therapy with doxazosin exhibit antithrombotic effects in patients with essential hypertension? 2) Are the potential antithrombotic effects of doxazosin different to the effects of an ACE inhibitor? 3) Is there a relation between the antihypertensive effect and the antithrombotic effect of these antihypertensive agents?
The co-primary outcomes are changes in endothelial function assessed by flow mediated vasodilatation, and in haemostatic function measured by the generation of thrombin-antithrombin complex.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 71
- Primary mild-to-moderate hypertension
- Pregnancy and lactation
- Recent (6 months) malignant disease or ongoing treatment for malignancy
- No absolute indication or contraindication for any of the study drugs
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Alpha receptor blocker Doxazosin Doxazosin tablets 8 mg od for 12 weeks ACE inhibitor Ramipril Ramipril tablets 10 mg od for 12 weeks
- Primary Outcome Measures
Name Time Method Thrombin generation 12 weeks Thrombin-Antithrombin complex (TAT)
Endothelial function 12 weeks Forearm post-ischemic flow mediated dilatation
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Karolinska Institutet, Daprtment of Clinical Sciences, Danderyd Hospital, Cardiovascular Research Laboratory
🇸🇪Stockholm, Sweden